A 52-year-old woman with ischemic cardiomyopathy (LVEF 28%) is admitted with recurrent episodes of non-sustained ventricular tachycardia (NSVT) on Holter monitoring. She is already on optimal medical therapy (ACE inhibitor, beta-blocker, and aldosterone antagonist) and has no contraindications to device therapy. What is the most appropriate next step in management?

Explanation

## Clinical Context: Primary Prevention in Ischemic Cardiomyopathy This patient has: - **Severely reduced LVEF (28%)** — high risk for sudden cardiac death (SCD) - **Ischemic cardiomyopathy** — scar-related VT substrate - **NSVT on monitoring** — independent risk factor for sustained VT/VF - **Optimal medical therapy** already in place ## Guideline-Based Decision ```mermaid flowchart TD A[LVEF ≤ 35% + Ischemic CM]:::outcome --> B{Prior cardiac arrest or sustained VT?}:::decision B -->|Yes: Secondary prevention| C[ICD]:::action B -->|No: Primary prevention| D{LVEF ≤ 35% on optimal meds?}:::decision D -->|Yes| E[ICD for primary prevention]:::action D -->|No| F[Optimize medical therapy]:::action C --> G[Implant within 40 days]:::action E --> G ``` ## Key Point: **LVEF ≤35% on optimal medical therapy is an indication for primary prevention ICD in ischemic cardiomyopathy, regardless of NSVT status.** NSVT is an additional risk marker but not required for the indication. ## High-Yield: ICD Indications in Ischemic Cardiomyopathy | Indication | LVEF Threshold | Timing | |---|---|---| | **Secondary prevention** (prior VF/sustained VT) | Any | Within 40 days of event | | **Primary prevention** (no prior arrest) | ≤35% on optimal meds | ≥40 days post-MI | | NSVT + inducible VT on EPS | ≤40% | After EPS | ## Clinical Pearl: NSVT in the setting of reduced LVEF is a **risk marker**, not a treatment indication by itself. However, combined with LVEF ≤35%, it strengthens the case for ICD insertion. The presence of NSVT does **not** mandate EPS/ablation in primary prevention — ICD is preferred because it protects against both VT and sudden VF. ## Why Not Ablation First? - Ablation is reserved for **incessant VT**, **frequent ICD shocks**, or **secondary prevention** after failed antiarrhythmics - In primary prevention with reduced LVEF, ICD is superior because it covers the full spectrum of arrhythmia risk - EPS/ablation may be considered as adjunctive therapy if ICD shocks become frequent ## Why Not Increased Medical Therapy? - Patient is already on triple therapy (ACE-I, beta-blocker, MRA) - Mexiletine and other Class I agents have **not** been shown to reduce mortality in ischemic cardiomyopathy - Only beta-blockers, ACE-I/ARB, and aldosterone antagonists have mortality benefit [cite:Harrison 21e Ch 297; 2017 ACC/AHA/HRS Focused Update on VT/VF]